caa a22 4500 477070248 CHVBK 20180405111423.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/BF01690510 doi (NATIONALLICENCE)springer-10.1007/BF01690510 Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants [Elektronische Daten] [F. Simondon, A. Yam, J. Gagnepain, S. Wassilak, B. Danve, M. Cadoz] A diphtheria and tetanus toxoid two-component acellular pertussis vaccine (DTaP), consisting of 25 μg glutaraldehyde-detoxified pertussis toxin (PT) and 25 μg native filamentous hemagglutinin (FHA), was compared with diphtheria and tetanus toxoid whole-cell pertussis vaccine (DTwP) in a randomized, double-blind manner in 286 Senegalese infants inoculated at two, four, and six months of age. In infants receiving DTaP a significantly lower rate of local reactions, crying and fever was observed than in infants receiving DTwP. One month after the third dose, the geometric mean titres for FHA antibodies were higher in the DTaP group, whereas increases in PT antibody titres were higher in the DTwP group. More than 90% of the infants had a fourfold or more increase in antibodies to both PT and FHA with either vaccine. Diphtheria, tetanus, and polio antibody responses were also measured and found to be comparable between the two groups. The results of this pilot study support the implementation of a field trial to compare the protective efficacy of these vaccines against pertussis in the same setting. Springer-Verlag, 1996 Simondon F. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut Yam A. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut Gagnepain J. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut Wassilak S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA aut Danve B. Pasteur-Mérieux Sérums et Vaccins, Lyon, France aut Cadoz M. Pasteur-Mérieux Sérums et Vaccins, Lyon, France aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/12(1996-12-01), 927-932 0934-9723 15:12<927 1996 15 10096 https://doi.org/10.1007/BF01690510 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01690510 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Simondon F. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut NATIONALLICENCE 700 1- Yam A. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut NATIONALLICENCE 700 1- Gagnepain J. Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Dakar, Senegal aut NATIONALLICENCE 700 1- Wassilak S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA aut NATIONALLICENCE 700 1- Danve B. Pasteur-Mérieux Sérums et Vaccins, Lyon, France aut NATIONALLICENCE 700 1- Cadoz M. Pasteur-Mérieux Sérums et Vaccins, Lyon, France aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/12(1996-12-01), 927-932 0934-9723 15:12<927 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer